Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01794624 · ClinicalTrials.gov registry record · NA
Biobehavioral Pain Management in TMD
A NA study of Temporomandibular Joint Disorder, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 2
- Study locations
NCT01794624: Completed NA study of Temporomandibular Joint Disorder, sponsored by Johns Hopkins University.
NCT01794624 is a NA study of Temporomandibular Joint Disorder that has completed, run by Johns Hopkins University. The registered enrollment target is 300 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01794624, a NA study of Temporomandibular Joint Disorder, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 2
- Study locations
Study Summary
TMD is a poorly understood chronic pain disorder that affects up to 15% of the adult population, notably impacting women, is linked to greater healthcare utilization, and associated with multiple pain-related co-morbidities. Pain-related catastrophizing (CAT) and sleep continuity disturbance (SCD) are well established modifiable risk factors for TMD and other idiopathic pain conditions. Neither the causal status nor the neurobiological mechanisms by which these factors exert their effects on clinical pain have been established. We propose that CAT and SCD influence clinical pain through shared alterations in pain modulation and key neurobiological pathways, including amplified inflammatory activity, autonomic activity, and adrenocortical functioning. Beyond these shared mechanisms, however, we propose to determine whether pre-sleep CAT increases cortical arousal during sleep. The cognitive dimensions of pre-sleep arousal, particularly rumination and negative sleep-related thoughts, are central to the phenomenology of insomnia. Extending this notion, we propose that CAT in those experiencing ongoing clinical pain fosters sleep disturbance owing to increased pre- and peri-sleep cognitive arousal. Moreover, we propose that pre-sleep CAT is related to subtle variations in objective indices of fragmented sleep (e.g., cortical arousal). We will examine key hypotheses derived from this framework using a brief, prospective randomized experiment, which will permit careful analysis of the temporal patterning of how changes in either CAT or SCD influence each other and contribute to alterations in pain modulatory systems, key nociceptive mechanisms, and clinical pain. Women experiencing at least moderate chronic TMD pain (N=225) who demonstrate at least mild trait catastrophizing and meet at least subclinical insomnia criteria (SCD) will be randomly assigned to: 1) cognitive therapy for catastrophizing (CT-CAT); 2) behavior therapy for sleep disturbance (BT-SCD); or 3) TMD ed
Primary Outcome
Two interventions that experimentally manipulate TMJD pain risk factors (behavioral therapy focusing on sleep continuity disturbance \[BT-SCD\] and cognitive therapy focusing on pain-related catastrophizing \[CT-CAT\]) will be compared with a control (education about TMJD and its treatments), to assess changes in and temporal relationships of pain modulation, pain-evoked inflammatory activity and clinical pain. PAIN MODULATION: Mid change (Visit 6 to Visit 8) in temporal summation and Condition
Conditions Studied
Interventions
- BEHAVIORAL Cognitive Therapy for Catastrophizing
- BEHAVIORAL Behavioral Therapy for Sleep Continuity Disturbance
Study Locations (2)
Maryland
- University of Maryland Dental School: Brotman Facial Pain Clinic - Baltimore
- Johns Hopkins Bayview Meidical Center: Behavioral Medicine Research Laboratory - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2013-04 |
| Est. Completion | 2018-06 |
| Phase | NA |
What the finished NCT01794624 record still lists
NCT01794624 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Temporomandibular Joint Disorder appearing as the primary indexed condition, and to 2 interventions - of which Cognitive Therapy for Catastrophizing is the first listed.
NCT01794624 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01794624 about?
NCT01794624 is a clinical study titled "Biobehavioral Pain Management in TMD". TMD is a poorly understood chronic pain disorder that affects up to 15% of the adult population, notably impacting women, is linked to greater healthcare utilization, and associated with multiple pain-related co-morbidities. Pain-related catastrophizing (CAT) and sleep continuity disturbance (SCD) a...
What is the current status of trial NCT01794624?
This trial is currently completed. It is a NA study. The enrollment target is 300 participants. The study started on 2013-04. Estimated completion is 2018-06.
What conditions does trial NCT01794624 study?
This clinical trial studies the following conditions: Temporomandibular Joint Disorder.
What interventions are being tested in trial NCT01794624?
The interventions under investigation include: Cognitive Therapy for Catastrophizing (BEHAVIORAL), Behavioral Therapy for Sleep Continuity Disturbance (BEHAVIORAL).
Who is sponsoring clinical trial NCT01794624?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01794624 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01794624's enrollment target sits among peer trials
300 330th of 2000 higher than 1,630 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia